185 related articles for article (PubMed ID: 25652955)
1. EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France.
Polack B; Calvez T; Chambost H; Rothschild C; Goudemand J; Claeyssens S; Borel-Derlon A; Bardoulat I; Maurel F; Woronoff-Lemsi MC;
Transfusion; 2015 Jul; 55(7):1787-97. PubMed ID: 25652955
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
Alamelu J; Bevan D; Sorensen B; Rangarajan S
J Thromb Haemost; 2014 Dec; 12(12):2044-8. PubMed ID: 25315324
[TBL] [Abstract][Full Text] [Related]
3. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.
Björkman S
Haemophilia; 2011 Mar; 17(2):179-84. PubMed ID: 21299739
[TBL] [Abstract][Full Text] [Related]
4. Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).
Solano Trujillo MH; Stasyshyn O; Rusen L; Serban M; Lamas JL; Perina FG; Urasinski T; Oh M; Knowlton WB; Valenta-Singer B; Pavlova BG; Abbuehl B
Haemophilia; 2014 Sep; 20(5):674-81. PubMed ID: 24720694
[TBL] [Abstract][Full Text] [Related]
5. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
Roth DA; Kessler CM; Pasi KJ; Rup B; Courter SG; Tubridy KL;
Blood; 2001 Dec; 98(13):3600-6. PubMed ID: 11739163
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B.
Recht M; Pollmann H; Tagliaferri A; Musso R; Janco R; Neuman WR
Haemophilia; 2011 May; 17(3):494-9. PubMed ID: 21518148
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
Brinkhous KM; Sigman JL; Read MS; Stewart PF; McCarthy KP; Timony GA; Leppanen SD; Rup BJ; Keith JC; Garzone PD; Schaub RG
Blood; 1996 Oct; 88(7):2603-10. PubMed ID: 8839853
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.
Pochopien M; Tytuła A; Toumi M; Falk A; Martone N; Hakimi Z; Eriksson D
Adv Ther; 2024 Jun; 41(6):2307-2323. PubMed ID: 38652439
[TBL] [Abstract][Full Text] [Related]
10. Haemophilia B: impact on patients and economic burden of disease.
Gater A; Thomson TA; Strandberg-Larsen M
Thromb Haemost; 2011 Sep; 106(3):398-404. PubMed ID: 21833450
[TBL] [Abstract][Full Text] [Related]
11. BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.
Windyga J; Abbuehl BE; Hafeman AE
Expert Rev Hematol; 2014 Jun; 7(3):333-42. PubMed ID: 24832133
[TBL] [Abstract][Full Text] [Related]
12. Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain.
Rodríguez López M; Megías Vericat JE; Albo López C; Bonanad S
BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33051199
[TBL] [Abstract][Full Text] [Related]
13. Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study.
Windyga J; Lin VW; Epstein JD; Ito D; Xiong Y; Abbuehl BE; Ramirez JH
Haemophilia; 2014 May; 20(3):362-8. PubMed ID: 24251442
[TBL] [Abstract][Full Text] [Related]
14. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
J Med Econ; 2017 Apr; 20(4):337-344. PubMed ID: 27885871
[TBL] [Abstract][Full Text] [Related]
15. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
Wilmot HV; Hogwood J; Gray E
Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
Preijers T; Hazendonk HCAM; Liesner R; Chowdary P; Driessens MHE; Hart D; Keeling D; Laros-van Gorkom BAP; van der Meer FJM; Meijer K; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH; Mathôt RAA;
J Thromb Haemost; 2018 Nov; 16(11):2196-2207. PubMed ID: 30394056
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.
Shapiro AD; Di Paola J; Cohen A; Pasi KJ; Heisel MA; Blanchette VS; Abshire TC; Hoots WK; Lusher JM; Negrier C; Rothschild C; Roth DA
Blood; 2005 Jan; 105(2):518-25. PubMed ID: 15383463
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan.
Chang HH; Yang YL; Hung MH; Tsay W; Shen MC
J Formos Med Assoc; 2007 Apr; 106(4):281-7. PubMed ID: 17475604
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs for hemophilia B.
Mannucci PM; Franchini M
Expert Opin Emerg Drugs; 2014 Sep; 19(3):407-14. PubMed ID: 25098797
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
Davis J; Yan S; Matsushita T; Alberio L; Bassett P; Santagostino E
J Med Econ; 2019 Oct; 22(10):1014-1021. PubMed ID: 31094591
[No Abstract] [Full Text] [Related]
[Next] [New Search]